

Dr. Steven Horwitz

Dr. Horwitz is an Associate Attending in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City. He received his medical degree from Case Western Reserve University in Cleveland, Ohio, and continued his training with a residency at the University of Rochester, New York. He completed a fellowship at Stanford University Medical Center in Stanford, California.

Dr. Horwitz divides his time between the clinical care of lymphoma patients and clinical research. His clinical research focuses primarily on developing new therapies for T-cell, NK, and cutaneous lymphomas. He has developed a large clinical trial portfolio and clinical program at Memorial Sloan Kettering dedicated to these diseases. Through this program MSK has led or been instrumental in the development of several FDA approved therapies in T-cell lymphomas including pralatrexate, romidepsin, brentuximab vedotin, and belinostat that have greatly expanded treatment options for patients.

Currently, Dr. Horwitz serves as the lead of the clinical trial core of the Leukemia Lymphoma Society SCOR Grant: Translational discovery T-cell lymphoma. He is currently the principal investigator on eleven ongoing or recently completed prospective trials for patients with T-cell lymphoma. He serves on the executive committee of the International T-cell Registry, is a founding member of the U.S. Consortium for Cutaneous Lymphoma, and is a board member of the Cutaneous Lymphoma Foundation. He also serves on the NCCN non-Hodgkin Lymphoma Committee and has led efforts in developing new guidelines for PTCL, NK/T-cell, and cutaneous lymphomas.